# A Phase Ib Study of RC1416 Injection

> **NCT06911866** · PHASE1 · COMPLETED · sponsor: **Nanjing RegeneCore Biotech Co., Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Moderate to Severe Asthma

## Interventions

- **DRUG:** RC1416
- **DRUG:** RC1416 Placebo

## Key facts

- **NCT ID:** NCT06911866
- **Lead sponsor:** Nanjing RegeneCore Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-25
- **Primary completion:** 2025-09-25
- **Final completion:** 2025-09-25
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06911866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06911866, "A Phase Ib Study of RC1416 Injection". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06911866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*